Saltropium Special Precautions

Immediate hypersensitivity reactions may occur after administration of Salbutamol + Ipratropium Bromide (Saltropium), as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.
Ocular Complications: There have been isolated reports of ocular complications (i.e., mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) when aerosolized ipratropium bromide, either alone or in combination with an adrenergic β2-agonist, has escaped into the eyes.
Eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes from conjunctival congestion and corneal edema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately.
Patients must be instructed in the correct administration of Salbutamol + Ipratropium Bromide (Saltropium). Care must be taken not to expose the eyes to the aerosol or solution of Salbutamol + Ipratropium Bromide (Saltropium).
It is recommended that the nebulized solution be administered via a mouthpiece. If this is not available and a nebulizer mask is used, it must fit properly.
Patients who may be predisposed to glaucoma should be warned specifically to protect their eyes.
In the following conditions, Salbutamol + Ipratropium Bromide (Saltropium) should only be used after careful risk/benefit assessment, especially when doses higher than recommended are used: Insufficiently controlled diabetes mellitus, recent myocardial infarction, severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction.
Potentially serious hypokalemia may result from β2-agonist therapy. Additionally, hypoxia may aggravate the effects of hypokalemia on cardiac rhythm.
Patients with cystic fibrosis may be more prone to gastrointestinal motility disturbances.
In the case of acute, rapidly worsening dyspnea (difficulty in breathing), a doctor should be consulted immediately.
If higher than recommended doses of Salbutamol + Ipratropium Bromide (Saltropium) are required to control symptoms, the patient's therapy plan should be reviewed by a doctor.